Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses
(RTTNews) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. This means that patients receiving IMDELLTR
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.